My last IDRA share buy was at 3.26 on November 20th, which topped off my position. Today I purchased some shares in Foundation Medicine FMI which is owned 56.3% by Roche yet operates independently. "Oncology major Roche (RHHBY) recently announced that it has entered into a strategic collaboration agreement to acquire up to a 56.3% stake in Foundation Medicine, Inc. (FMI), a molecular information and genomic analysis company, on a fully diluted basis through a tender and acquisition of newly issued shares." That was January 14th.
It was at lows earlier this week, I've been following it (never owned it before) and went over their ER transcript in detail this week. I think it's vastly undervalued, since Roche added their $1B investment this year at $50 a share.
Thanks for sharing your picks, IDRA is my largest position and I intend to hold like you, for the growth we all see here.
The candle for the week shows a $0.49 gain if we use 3.68 as the close on the week, last Friday we closed at 3.19. I have Schwab saying it closed at 3.68, Stockcharts says 3.66, and Nasdaq says 3.69, go figure! Anyway, the way it is shaping up, it's like I said on November 13th, the chart is telling us we are going to break out, and on the heels of this week's momentum and positive news, the odds of this happening have only increased. Next week should be powerful running into ASH, and then lift off the following week, depending of course on what we hear. Looking good, the New Era for Idera is here.
Quin, you had the perfect 5 thumbs up, then I ruined it by giving you a 6th. Oh well, for a good post, thanks for bringing up 3.92, that's where they have a buy stop huh? Next week is when we take out that level, from the looks of today's action. So, when did you come into IDRA, are you looking to exit when we get to $5.25 or stay invested until double digits?
They're not that smart, but somebody is surely buying today. Amano said we'd likely have 20 trials going by year end 2016, I think we've got 6 trials either going now or with starts announced for early next year, but he's likely right in his statement. With several more likely partnerships and the accompanying funding, he's seeing the future. Still, shorts in my experience don't just pull up stakes and move based on fundamentals, or even a stock that starts an obvious run like we're seeing here. Thanks for the topic stockof 2013, will IDRA be the stockof2016 (?), that's my bet!
Sentiment: Strong Buy
When I looked at this and went over the transcript of the recent earnings call, and more, even the chart, there was only transparency and a growing company with much promise and at such a low price. So, this morning I invested here, and before the shares ran from my bid. I think we've seen the lows and also believe the biotech market is set to rally for the next several months.
You correctly called out FMI before Roche bought in for $1B last January when the stock more than doubled, that was a big win for investors. Now it trades for one third that value, hard to believe some didn't tender their shares. What is your opinion about buying that around $16? I think I have enough developmental biotech for now (AUPH).
That's a good lesson for others here, no position larger than 15%. I am paying attention to this lesson, and am glad you sent me to MRNS when you did. Sorry about CLVS!
Thanks Andre, I wouldn't have known about MRNS without you pointing to it. Something happened there today, volume exploded and price along with it. I'll look at AUPH now.
Great analogy Tau, "the big cranes" of MDA and GSK are now in place, the large buildings will now be built to hereafter define the skyline.
Since PPMD (Parent Project Muscular Dystrophy) announced it's collaboration with Idera on November 7, 2014, (just prior to Vince Milano' s hire) the Company has been carefully designing elements of this trial to maximize successful outcomes. Not surprisingly, prior research by independent third parties does justify the trial: "Over the last five years, we have demonstrated in preclinical studies that TLRs play a critical role in triggering inflammation in neuromuscular diseases such as Duchenne. Based on this research, we believe there is a clear scientific rationale for the evaluation of TLR antagonism as a potential treatment approach," said Kanneboyina Nagaraju, Ph.D., DVM, Professor of Integrative Systems Biology and Pediatrics at the George Washington University School of Medicine and Health Sciences and Children's National Health System.
Independent research published by investigators from Children's National Health System in Washington, DC, have demonstrated the role of TLRs in the pathogenesis of DMD. Results from this study showed a statistically significant 6.6-fold over expression of TLR 7 in the muscle fibers of patients with Duchenne compared with healthy controls aged 5 to 12 years. In addition, investigators reported that TLR 7 was also over expressed in pre-symptomatic infants, suggesting TLR activation is an early trigger of muscle inflammation in Duchenne."
The trial is scheduled to commence in 1H 2016. What is developed by Idera Pharma may potentially used in combination therapy with approved therapies such as Eteplirsen should Sarepta's campaign lead to its approval.
I find it interesting that the bullish daily/weekly charts are coincidental to the timing of the years biggest known catalysts (unknown catalysts like GSK partnership add to our conviction/chart strength). The weekly chart candle on Friday will only help point toward further gains.
I'm betting we will, Milano is gaining a lot of respect here for his 'under-promise/over-deliver' management style. As investors, we are learning that when it's quiet, no news flow, that there is a great deal going on that we may know nothing about. All that insider knowledge precludes insider buys, too.
I love to see our board members exchange heartfelt thanks and appreciation to each other, the shared values amongst us, it's another corner of our home where we have a strong common interest. All my best to everyone here, and a special prayer of protection against forces of evil that threaten our freedoms.
“Advances in our understanding of chronic kidney disease have opened up new treatment opportunities,” said John Lepore, GSK Senior Vice President and Head of the Metabolic Pathways and Cardiovascular Therapy Area Unit. “Idera’s antisense platform offers a new path to explore whether gene silencing technology can help stop or slow chronic kidney disease.”
When worldwide pharma giant GSK recognizes and steps up to partner with Idera, acknowledging the innovation and potential of Idera's 3GY platform, that shines a bright light on Idera's future in partnering with Big Pharma. This is a very significant marker of the New Era of Idera. If #GY does in fact "help stop or slow chronic kidney disease", the path to Idera's door by Big Pharma will get very crowded, countless lives will be saved, and investors here will get very rich.
Sentiment: Strong Buy
I can feel the change, we all can. This is our time, our Company is entering a new phase, it's been reinvented since Milano arrived, changing from the top down, and the inside out. Our groundbreaking scientific platforms are gaining worldwide recognition via MD Anderson Center and GSK. The WM data release is going to bring further dramatic validation and credibility to Idera. The new website reflects the evolution, marks the coming out of the powerhouse that Idera has become. The predominant shorts haven't figured it out yet, only the smart ones have covered. It's an exciting time for investors here.
Sentiment: Strong Buy
Nice heads up! Now you can find the combined trials summary in one place, big improvement, with links to each trial. What a great new look, it incorporates the value proposition and new mantra much more effectively. Patient centered focus.
We are early here, in cheap, but trials go for couple more years, with interim data reports. You can go to their website and click on the clincal trial links and read about each trial. I am no expert but absent catalysts of news, nearby, these stocks sell off and keep going lower, despite the prognosis of the trials. Your point about expected market for the indications, other than AML, being small is part of it, being far away from catalysts is the main issue for lack of interest in the stock. The chart looks bleak as well.
Yes, I'm just upset having just lost a fair amount of money here, with this management team and how they badly bungled the situation, as most here must be. Before they reported the last two quarters I read the posts as most long term holders weighed in with their own guesses as to what they thought, each of course having to guess based on different metrics. All because of managements refusal to give revenue projections per product or vendor. Everyone missed badly, the Company issued the dividend when they clearly had no business doing so, because even they didn't know what was going on. That did it for me. I went over to Horizon Pharma where they give very specific guidance and metrics. Since I sold here at $14, I've made back several dollars per share there, still not back to par but on my way. I won't be continuing to post here, but the wound ran deep enough that I wanted to express more than just selling my shares. You deserve to win, you post good facts as you see them, many good people here, it's a shame.
It's still a gamble with management that won't give guidance or answer questions on Earnings conference calls. They don't want to answer to guidance, it gives investors too much from which to measure their performance as a management team. Lode should be fired, he's destroyed two years of market cap in two quarters.